| Similar Articles |
|---|
 |
The Motley Fool
October 9, 2011
Eric Bleeker |
This Week's Stock Top Gainers and Laggards Energy makes a rebound as one of the three top performing sectors.   |
The Motley Fool
December 26, 2011
Matt Koppenheffer |
Last Week's Biggest Stock Laggards The market roared ahead last week, but some stocks and sectors weren't able to keep up with the rest of the market. |
The Motley Fool
December 19, 2011
Dan Caplinger |
You Probably Just Bought These Stocks More index moves demand investor attention. |
Chemistry World
February 23, 2015
Phillip Broadwith |
Valeant to buy Salix for $14.5bn Serial acquirer Valeant has agreed to buy gastroenterology specialist Salix Pharmaceuticals for $14.5 billion |
Chemistry World
March 25, 2015
Phillip Broadwith |
Valeant heads off Endo bid for Salix Valeant has flexed its acquisitive muscles to head off a rival bid for gastroenterology specialist Salix Pharmaceuticals. |
The Motley Fool
August 19, 2011
Cindy Johnson |
12 Pharmaceutical Stocks the Insiders Are Buying Folks in the know think these pharmaceutical stocks will rise. Should you join them? |
The Motley Fool
December 15, 2011
Luke Timmerman |
Vertex Names Jeff Leiden As New CEO, Staring Down Tough New Competition What does new leadership mean for Vertex's future? |
The Motley Fool
June 9, 2011
Brian D. Pacampara |
Vertex Pharmaceuticals Shares Plunged: What You Need to Know Shares of drug developer Vertex Pharmaceuticals sank as much as 13% after reporting initial data on their combination cystic fibrosis treatment. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
Investment Advisor
February 2007
Kara Stapleton |
Small Caps On Top Again The small-cap Russell 2000 Index made a comeback in 2006. |
The Motley Fool
November 16, 2011
David Williamson |
3 Biotechs Beating the Market The daily health-care news investors need to read. |
The Motley Fool
April 11, 2011
Jim Mueller |
A Missed Opportunity Cephalon showed up on my screen as a potential buy, but others liked it, too. |
The Motley Fool
December 2, 2010
Brian Orelli |
A Short FDA Delay. For What? GlaxoSmithKline and Valeant aren't saying. |
BusinessWeek
June 16, 2011
Mider & McCracken |
M&A: The Markets Love a Buyer Contrary to conventional wisdom, the announcement of an acquisition is likely to lift the stock price of the company doing the buying. |
Chemistry World
November 24, 2014
Andy Extance |
Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis. |
The Motley Fool
January 21, 2011
Brian Orelli |
Mark Your Calendar, Drug Investors Vertex announces that the Food and Drug Administration has accepted its New Drug Application to market telaprevir. |
